期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米为主方案治疗难治/复发轻链型多发性骨髓瘤 被引量：2

Effects of bortezomib on refractory or relapsed light-chain multiple myeloma
原文传递
导出
摘要 目的了解硼替佐米对难治/复发性轻链型多发性骨髓瘤的疗效。方法采用BD/BP、BAD/BAP、BAEP及BVAD方案治疗14例轻链型MM患者。结果14例患者中,CR1例,nCR2例,PR5例,ORR8例。6例合并肾功能不全患者与8例肾功能正常患者的疗效相近。不良反应主要有乏力、胃肠道反应、末梢神经炎、血小板减少等,均可耐受。结论硼替佐米对部分已对化疗耐药的难治/复发性轻链型MM仍然有效,且效果显著。 Objective To elucidate the curative effects and toxicity of bortezomib on refractory or relapsed light-chain multiple myeloma （MM）, Methods Fourteen patients with refractory or relapsed light-chain MM were treated with BD/BP, BAD/BAP, and BAEP or BVAD, Results The complete, near complete, and partial remission rate was 7.1%（1/14）, 14.2%（2/14）, and 35.7%（5/11）, respectively, with an overall response rate of 57.1%. The response rate of patients with and without renal impairment was similar. The main toxicities were languor, gastrointestinal side effects, peripheral neuropathy, thrombocytopenia. Conclusion Patients with refractory or relapsed MM resistant to chemotherapy can respond to bortezomib. The regimen is safe and its side effects are tolerable.
作者 吴亚妹 王志红 马健 曹永彬 徐丽昕 刘蓓 闫蓓 刘周阳 吴晓雄 高春记 达万明
机构地区 解放军总医院 解放军总医院血液科
出处 《军医进修学院学报》 CAS 2010年第1期19-21,共3页 Academic Journal of Pla Postgraduate Medical School
关键词 多发性骨髓瘤 硼替佐米 治疗结果 Multiple Myeloma Bortezomib Treatment Outcome
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Richardson PG, Barlogie B, Berenson J, et al. Extended fallow- up of a phase Ⅱ trial in relapsed, refractory multiple myeloma [ J ] . Cancer, 2006, 106 (6) : 1316-1319.
  • 2吴晓雄,于力,黄文荣,赵瑜,王全顺,薄剑,李菲,高春记.硼替佐米治疗难治/复发性多发性骨髓瘤的疗效观察[J].临床血液学杂志,2007,20(5):268-269. 被引量：15
  • 3Chanan-Khan A, Miller KC. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma[ J ]. Leuk Lymphoma, 2005, 46( 7 ):1103-1104.
  • 4Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma [ J ] . Blood, 2007, 109 ( 7 ) : 2767-2772.
  • 5Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietie stem cell transplantation. Myeloma Subcommitte for the EBMT [ J ] . Br J haematol, 1998, 102 (5) : 1115-1123.
  • 6Knudsen LM, Hippe E, Hjorth M, et al. Renal function in newly diagnosed muhiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group [ J ] . Eur J Haematol, 1994, 53 ( 4 ) : 207-212.
  • 7Knudsen LM, Hjorth M, Hippe E, et al. Renal failure in multiple myeloma : reversibility and impact on the prognosis. Nordic Myeloma Study Group [ J ] . EurJ Haematol, 2000, 65 ( 3 ) : 175-181.

二级参考文献7

  • 1RICHARDSON P G,BARLOGIE B, BERENSON J, et al. Extended follow-up of a phase Ⅱ trial in relapsed , refractory multiple myeloma [J]. Cancer, 2006,106:1316-1319.
  • 2CHANAN-KENA A, MILLER K C. Veleade, Doxil and Thalidomide(VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma[J]. Leukemia&lymphoma, 2005,46:1103-1104.
  • 3BLADEJ, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation . Myeloma Subcommitte for the EBMT[J]. Br J haematol, 1998, 102:1115-1123.
  • 4ADAMS J. The proteasome:structure, function , and role in the cell[J]. Cancer Treat Rev, 2003,29:3-9.
  • 5SHAH S,POTTER M,CALLERY M. Ubiquitin proteasome pathway: implication and advances in cancer therapy[J]. Surgical Oncology, 2001,10:43-52.
  • 6KARIN M, CAO Y, GRETEN F, et al. NF-KB in cancer :from innocent bystander to major culprit[J]. Nature Rev Cancer, 2002,2:301-310.
  • 7WU K L, VAN WIERINGEN W, VELLENGA E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice[J]. Haematologica, 2005,90:996-997.

共引文献14

同被引文献17

  • 1Dimopoulos MA,Kastritis E,Rosinol L,et al.Pathogene-sis and treatment of renal failure in multlple myeloma[J].Leukemia,2008,22(8):1485-1493.
  • 2吴晓雄,于力,黄文荣,赵瑜,王全顺,薄剑,李菲,高春记.硼替佐米治疗难治/复发性多发性骨髓瘤的疗效观察[J].临床血液学杂志,2007,20(5):268-269. 被引量：15
  • 3Hainsworth JD, Spigel DR, Barton J, et al. Weekly treatment with bortezomib for patients with recurrent or refractory muhiple myeloma: a phase 2 trial, of the Minnie Pearl Cancer Research Network. Cancer, 2008, 113: 756-771.
  • 4Blad6 J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantatiou.Myeloma Committee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 1998, 102:1115-1231.
  • 5Klein B. Growth factor sin the pathogenesis of multiple myeloma. In Gahrton G, Durie B,eds. Multiple Myeloma. New York: Oxford University Press, 1996: 73-82.
  • 6Palnmbo A, Amhrosini MT, Benevolo G, et al.Bortezomib,melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, 109: 2767-2772.
  • 7Harousseau JL, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of all IFM phase II study. Haematologica, 2006, 91: 1498- 1505.
  • 8Roussou M, Kastritis E, Migkou M, et al. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma, 2008, 49: 890-895.
  • 9刘志刚,季杰,常红.多发性骨髓瘤诊治进展[J].现代临床医学,2008,34(5):386-388. 被引量：8
  • 10姜松青,苏明,石晓峰.以急性肾功能衰竭为首发表现的多发性骨髓瘤3例及文献复习[J].罕少疾病杂志,2008,15(6):34-36. 被引量：2

引证文献2

二级引证文献5

军医进修学院学报
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部